Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

Kotaro Shibahara, Manabu Yamamoto, Yoshihiro Kakeji, Hisanobu Sakata, Yoshihiko Maehara

Research output: Contribution to journalArticle

Abstract

The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

Original languageEnglish
Pages (from-to)1779-1784
Number of pages6
JournalAnticancer research
Volume28
Issue number3 B
Publication statusPublished - May 1 2008

Fingerprint

Tegafur
Uracil
Leucovorin
Colorectal Neoplasms
Retrospective Studies
Survival
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shibahara, K., Yamamoto, M., Kakeji, Y., Sakata, H., & Maehara, Y. (2008). Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer. Anticancer research, 28(3 B), 1779-1784.

Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer. / Shibahara, Kotaro; Yamamoto, Manabu; Kakeji, Yoshihiro; Sakata, Hisanobu; Maehara, Yoshihiko.

In: Anticancer research, Vol. 28, No. 3 B, 01.05.2008, p. 1779-1784.

Research output: Contribution to journalArticle

Shibahara, K, Yamamoto, M, Kakeji, Y, Sakata, H & Maehara, Y 2008, 'Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer', Anticancer research, vol. 28, no. 3 B, pp. 1779-1784.
Shibahara K, Yamamoto M, Kakeji Y, Sakata H, Maehara Y. Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer. Anticancer research. 2008 May 1;28(3 B):1779-1784.
Shibahara, Kotaro ; Yamamoto, Manabu ; Kakeji, Yoshihiro ; Sakata, Hisanobu ; Maehara, Yoshihiko. / Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer. In: Anticancer research. 2008 ; Vol. 28, No. 3 B. pp. 1779-1784.
@article{73a97ad6de8a4f8caa9f8f64e5f98dbb,
title = "Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer",
abstract = "The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8{\%} in the S-l group, and 11.1{\%} in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.",
author = "Kotaro Shibahara and Manabu Yamamoto and Yoshihiro Kakeji and Hisanobu Sakata and Yoshihiko Maehara",
year = "2008",
month = "5",
day = "1",
language = "English",
volume = "28",
pages = "1779--1784",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

AU - Shibahara, Kotaro

AU - Yamamoto, Manabu

AU - Kakeji, Yoshihiro

AU - Sakata, Hisanobu

AU - Maehara, Yoshihiko

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

AB - The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

UR - http://www.scopus.com/inward/record.url?scp=45949105002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949105002&partnerID=8YFLogxK

M3 - Article

C2 - 18630459

AN - SCOPUS:45949105002

VL - 28

SP - 1779

EP - 1784

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -